Skip to main content

Table 3 Best Response to PLD Therapy

From: A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

Best Response All Patients
N = 125
Patients with Prior Anthracycline Therapy N = 70 Response by Line of Treatment
    1st/2nd Line ≥ 3rd Line
    N = 65 N = 58
  No. Patients (%)
Complete response 6 (4.8) 2 (2.9) 4 (6.2) 2 (3.4)
Partial response 47 (37.6) 22 (31.4) 27 (41.5) 19 (32.8)
Stable disease 37 (29.6) 25 (35.7) 15 (23.1) 22 (37.9)
Progressive disease 28 (22.4) 17 (24.3) 18 (27.7) 10 (17.2)
Not determined 7 (5.6) 4 (5.7) 1 (1.5) 5(8.6)